No Detail Found!

Differences of HBME-1 Expression in Thyroid Follicular Adenoma and Follicular Thyroid Carcinoma by Ultrasound-guided Fine-needle Aspiration Biopsy.

Author(s)
Junsong Wang Department of Electrical Diagnosis, The Second Hospital of Jilin University, Jilin Province, 130041, China
Li Xu Department of Laboratory Medicine, The Second Hospital of Jilin University, Jilin Province, 130041, China
Xiaosen Xu Department of Electrical Diagnosis, Changchun Traditional Chinese Medicine Hospital, Jilin Province, 130000, China
Xin Wang Department of Laboratory Medicine, The First Clinical Hospital of Bethune Medical, Jilin University, Jilin Province, 130021, China
Abstract
Objective: To investigate the differences in human bone marrow endothelial cell marker 1 (HBME-1) expression in thyroid follicular adenoma (FA) and follicular thyroid carcinoma (FTC) by ultrasound-guided fine-needle aspiration biopsy. Study Design: An observational study. Place and Duration of Study: The Department of Electrical Diagnosis, The Second Hospital of Jilin University, Jilin Province, China, from January 2017 to April 2018. Methodology: Forty-five patients with FTC were selected as FTC group, and 45 patients with FA were selected as FA group. Ultrasound-guided fine-needle aspiration biopsy specimens from two groups were analyzed for HBME-1 expression. Sensitivity, specificity, and accuracy of HBME-1 expression by ultrasound-guided fine-needle aspiration biopsy specimens in FTC group were analyzed using HBME-1 expression in the pathological tissues as criteria. Results: The positive expression rate of HBME-1 in ultrasound-guided fine-needle aspiration biopsy specimens was higher in the FTC group than that in the FA group (p=0.003). The sensitivity, specificity, and accuracy of HBME-1 expression by ultrasound-guided fine-needle aspiration biopsy specimens in the FTC group were 77.78% (28/36), 88.89% (8/9) and 80.00% (36/45), respectively. Conclusion: HBME-1 detection with ultrasound-guided fine-needle aspiration biopsy may be useful clinically to pick out cases with follicular thyroid carcinoma, and that thyroid follicular adenoma cases need close follow-up.
Publication Details
Page(s) 337-340
DOI DOI not available
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 29, Issue: 4, Year: 2019

Request the full text from PASTIC

References
NicolsonNG,MurthaTD,DongW,PaulssonJO,ChoiJ,BarbieriAL, 2018.Comprehensive genetic analysis of follicular thyroid carcinoma predicts prognosis independent of histology,J Clin Endocrinol Metab 103 2640 -50
MishraA,KumarC,ChandG,AgarwalG,AgarwalA,VermaAK, 2016.Long-term outcome of follicular thyroid carcinoma in patients undergoing surgical intervention for skeletal metastases,World J Surg 40 562 -9
StensonG,NilssonIL,MuN,LarssonC,LundgrenCI,JuhlinCC, 2016.Minimally invasive follicular thyroid carcinomas: prognostic factors,Endocrine 53 505 -11
SponzielloM,LavaroneE,PegoloE,DiLC,PuppinC,RussoMA, 2013.Molecular differences between human thyroid follicular adenoma and carcinoma revealed by analysis of a murine model of thyroid cancer,Endocrinology 154 3043 -53
BrownC,ManganoW,ThompsonS,RichmondB, 2018.Factors predicting thyroid malignancy in fine needle aspiration biopsy specimens classified as atypia of uncertain significance/ follicular lesion of uncertain significance,Am Surg 84 1207 -13
Abu-SinnaE,HasanMY,El-DeftarMM,AmerSA,AbdelsalamLO,NakhlaJA, 2018.Galectin-3 and HBME-1 expression on agarose cell blocks from fine-needle aspirates of follicular cell-derived thyroid tumors,J Cytol 35 27 -32
MurtezaogluAR,GucerH, 2017.Diagnostic value of TROP-2 expression in papillary thyroid carcinoma and comparison with HBME-1,and cytokeratin 19. Pol J Pathol 68 1 -10
ArcoliaV,JourneF,RenaudF,LeteurtreE,GabiusHJ,RemmelinkM, 2017.Combination of galectin-3, CK19 and HBME-1 immunostaining improves the diagnosis of thyroid cancer,Oncol Lett 14 4183 -9
MoyanoL,FrancoC,CarreñoL,RobinsonP,SánchezG., 2004.HBME-1 and cyclin D1 as diagnostic markers for follicular thyroid carcinoma,Rev Med Chil 132 279 -84
CheahWK, 2007.Thyroid cancer: diagnosis and management,Singapore Med J 48 107 -12
LenggenhagerD,MaggioEM,MochH,Rössle M. HBME, 2013.-1 expression in hyalinizing trabecular tumours of the thyroid gland,Histopathology 62 1092 -7
TollenaarRA,van KriekenJH,van SlootenHJ,BruinvelsDJ,NelemansKM,van den BroekLJ, 1998.Immunohistochemical detection of p53 and Bcl-2 in colorectal carcinoma: No evidence for prognostic significance,Br J Cancer 77 1842 -7
LiuZ,ZhouG,NakamuraM,KoikeE,LiY,OzakiT, 2011.Encapsulated follicular thyroid tumor with equivocal nuclear changes, so-called well-differentiated tumor of uncertain malignant potential: A morphological, immunohistochemical, and molecular appraisal,Cancer Sci 102 288 -94
JeongSH,HongHS,LeeEH, 2016.Can nodular hyperplasia of the thyroid gland be differentiated from follicular adenoma and follicular carcinoma by ultrasonography?,Ultrasound Q 32 349 -55
CossuA,LissiaA,DedolaMF,DeianaA,FaeddaR,PalmieriG, 2005.Classic follicular dendritic reticulum cell tumor of the lymph node developing in a patient with a previous inflammatory pseudotumor-like proliferation,Hum Pathol 3 207 -11
PfeiferA,WojtasB,Oczko-WojciechowskaM,KukulskaA,CzarnieckaA,EszlingerM, 2013.Molecular differential diagnosis of follicular thyroid carcinoma and adenoma based on gene expression profiling by using formalin-fixed paraffinembedded tissues,BMC Med Genomics 6 38 -
RezkS,KhanA, 2005.Role of immunohistochemistry in the diagnosis and progression of follicular epithelium-derived thyroid carcinoma,Appl Immunohistochem Mol Morphol 13 256 -64
OmiY,ShibataN,OkamotoT,ObaraT,KobayashiM., 2012.The role of CD147 in the invasiveness of follicular thyroid carcinoma cells,Thyroid 22 383 -94
De MatosPS,FerreiraAP,DeOFF,AssumpçãoLV,MetzeK,WardLS, 2005.Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy,Histopathology 47 391 -401
CaseyMB,LohseCM,LloydRV, 2003.Distinction between papillary thyroid hyperplasia and papillary thyroid carcinoma by immunohistochemical staining for cytokeratin 19, galectin-3, and HBME-1,Endocr Pathol 14 55 -60
ColiA,BigottiG,ParenteP,FedericoF,CastriF,MassiG, 2007.Atypical thyroid nodules express both HBME-1 and galectin-3, two phenotypic markers of papillary thyroid carcinoma,J Exp Clin Cancer Res 26 221 -7
ZhuX,SunT,LuH,ZhouX,LuY,CaiX, 2010.Diagnostic significance of CK19, RET, galectin-3 and HBME-1 expression for papillary thyroid carcinoma,J Clin Pathol 63 786 -9
0

Citations

0

Downloads

51

Views